Report Archive
All Research
Page 40 of 45 · 1072 reports
41/100
Dongfang Electric: A Long-Term Business Owner's Perspective
China's platform-scale leader in power-generation equipment, spanning thermal, hydro, nuclear, gas, wind, and solar with sustained order growth. Free cash flow trails accounting profit meaningfully, and the A-share price at roughly 33x P/E already prices in improvement in heavy-duty gas turbines and nuclear power, leaving no margin of safety. Rating: Watch.
21/100
HYLink Digital: A Long-Term Owner's Investment Analysis
Rating Avoid. Revenue has shrunk roughly 90% over four years, the company has posted four straight years of losses, and net assets are nearly depleted, with a regulatory record of related-party fund occupation and false disclosure. At 8.43 yuan, the current price sits far above an intrinsic value range of 0.2-5.5 yuan; this is a state-capital turnaround option, not a proven compounder. Rating Avoid: a governance-impaired, balance-sheet-fragile restructuring story already pricing in a transformation option.
43/100
50Buffett
Western Superconducting: A Long-Term Enterprise Value Analysis
A niche leader in high-end titanium alloys, low-temperature superconductors, and high-performance superalloys, with genuine certification and process barriers; but free cash flow is markedly weaker than accounting profit, governance drew regulatory warnings over the past two years, and a PE (TTM) of about 57x overpays for growth expectations, leaving no margin of safety. Rating: Watch.
44/100
83Buffett
Agilent Technologies: A Study from a Long-Term Business Owner's Perspective
A high-quality laboratory tools and services company whose CrossLab services/consumables franchise is highly sticky, with solid cash flow and low debt. At the current $113.78, mid-single-digit growth is already fully priced in and the margin of safety is insufficient; rating Watch, with an ideal buy zone of $70-85.
45/100
73Buffett
AbbVie: In-Depth Research from a Long-Term Business Owner's Perspective
AbbVie has cleared the Humira patent cliff, with Skyrizi/Rinvoq taking over as twin engines (together about 42% of 2025 revenue), backed by strong cash flow and a solid dividend; at the current $212.30 the margin of safety is thin and book equity is negative, so the rating is Watch, with an ideal buy range of $155-180.
47/100
71Buffett
Abbott Laboratories Long-Term Value Investment Research
Abbott Laboratories is a high-quality healthcare company powered by four engines: medical devices, diagnostics, nutrition, and established pharmaceuticals. Its cash generation is solid and its dividend has risen for 54 consecutive years, but the current price of USD 88.38 offers limited margin of safety while the Exact Sciences acquisition raises leverage. Rating Watch: an attractive long-term compounder, but the ideal buy zone is USD 70-80.
45/100
Arch Capital Group Ltd. Deep Value Research
A high-quality insurer built on disciplined underwriting and multi-platform diversification, with book value per share compounding at roughly 16% CAGR over six years and sustained buybacks accreting per-share value. At about $95.87 it trades near 1.45x book, reasonable but only slightly cheap, with a limited margin of safety. Rated Cautious Buy, with an ideal buy range of $80-90.
48/100
96Buffett
Adobe Investment Research from a Long-Term Business Owner's Perspective
Adobe is a high-quality subscription software platform across creative, document, and marketing workflows, with gross margins near 90%, very strong cash flow, and net leverage close to zero. The company is being repriced for AI risk, while the current price of $253.37 is roughly 10x free cash flow and the ideal buy range is $220-280. Research rating Cautious Buy: a durable compounder with improved odds, but not enough margin of safety for an indiscriminate large position.
49/100
Analog Devices Deep Value Investment Research
Analog Devices is a high-quality analog semiconductor leader, with industrial and automotive contributing 75% of revenue and cash flow that has long exceeded accounting earnings. The core thesis is that the business is excellent, but the current price of about $398.05 implies roughly 43 times conservative owner earnings and leaves valuation far ahead of fundamentals. Research rating Watch: a durable compounder worth tracking closely, with an ideal buy zone of $150 to $200.
52/100
72Buffett
Autodesk: A Deep Value Investment Analysis
A high-stickiness leader in professional design software, with FY2026 recurring revenue at 97% of total and free cash flow of 2.4 billion dollars. But at roughly 244 dollars the stock sits in the optimistic zone, SBC erodes true earnings, and the margin of safety is thin. Rating Watch: a high-quality compounder priced for optimism rather than safety; ideal buy range 140-180 dollars.
40/100
42Buffett
American Electric Power In-Depth Value Investment Analysis
A high-quality regulated grid leader, but the 2026-2030 $78 billion capital plan relies heavily on equity financing and dilution risk is real; at about $129 it lacks a margin of safety, with an ideal entry range of $95-110.
47/100
Alnylam Pharmaceuticals Deep Value Investment Analysis
Alnylam is an RNAi innovator that reached its first full-year profit in 2025, with AMVUTTRA driving rapid commercialization. The core thesis is that the business has moved beyond a platform story, but revenue concentration, SBC, and financing complexity leave limited margin of safety at about $299. Research rating Watch: a durable company may be emerging, but an ideal entry point is closer to $200-240.
48/100
92Buffett
Applied Materials Deep Value Investment Research
Applied Materials is a leading semiconductor equipment company with the broadest product portfolio, an AGS service business that strengthens recurring revenue, and a net-cash balance sheet with strong cash flow. The core thesis is that business quality is high, but the current price of USD 426.85 at roughly 44x PE has already pulled forward too much AI-cycle optimism. Report rating Watch: the ideal buy range is USD 140-190.
43/100
67Buffett
Amgen Inc. Deep-Dive Value Investing Analysis
A high-quality but currently not-cheap mature biopharma asset; under a patent cliff, Medicare price cuts and a heavier balance sheet after the Horizon acquisition, the ~$331 price lacks a margin of safety, with an ideal buy range of $240-280. Rating: Watch.
50/100
49Buffett
AppLovin Corporation In-Depth Value Investment Research
AppLovin is now essentially a focused ad-tech platform centered on Axon after selling its Apps business. The core thesis is that cash generation and operating leverage are exceptional, but the roughly $482 share price already prepays for many years of high growth and leaves little margin of safety. Rating Watch: a high-quality business, but the ideal entry range is $180 to $260.
55/100
59Buffett
Arm Holdings: A Deep-Dive Value Analysis
The leading CPU-architecture IP platform, with exceptionally strong ecosystem and network effects; but at roughly $257 the stock trades at about 300x earnings and a 0.33% FCF yield, leaving the valuation an order of magnitude too rich with no margin of safety. Rating Watch: a superb business at a price that prices in a decade of flawless execution, ideal entry $30–50.
52/100
Axon Enterprise: A Deep Value Investing Analysis
A public-safety operating-system platform with 1.49 billion in ARR, 125% NRR, and a moat that is still widening; but at roughly 401 dollars it trades at 85x PE, prices in years of the future, leaves no margin of safety, and is worth buying only around 140 to 210 dollars. Rating Watch: a high-quality business at a high-quality price overshoot.
44/100
70Buffett
Booking Holdings: A Deep Value Investing Analysis
The global leader in accommodation OTA, asset-light with high cash flow and free cash flow that has long exceeded net profit; at about $157 the price offers almost no discount to conservative intrinsic value but a discount to fair value, so Cautious Buy, with an ideal buy range of $130-150.
42/100
40Buffett
Baker Hughes In-Depth Value Investing Analysis
Baker Hughes is transitioning from cyclical oilfield services toward an 'oilfield services + IET' hybrid, with IET orders and backlog lifting business quality; but at roughly $67 it sits at the upper edge of neutral value, the Chart acquisition raises leverage, and it lacks a margin of safety, so the ideal buy range is $45-55.
43/100
65Buffett
Coca-Cola Europacific Partners: A Deep Value Investing Analysis
The world's largest independent Coca-Cola bottler, with a simple business and solid cash flow. But at roughly $93 it sits at the upper edge of its fair-value range, and its free-cash-flow yield is only slightly above Treasuries, leaving an inadequate margin of safety, with an ideal buy of $67-78. Rating: Watch — a good business, but not yet a good price.
51/100
97Buffett
Cadence Design Systems: A Deep Value Investing Analysis
An EDA oligopoly leader with a strong moat and excellent cash flow; but at roughly $353 the stock trades at 87x earnings and 76x conservative owner earnings, far above even the optimistic range with no margin of safety, with an ideal buy point below $130. Rating Watch: a superb business whose price has run well ahead of value.
42/100
70Buffett
Comcast: A Deep Value-Investing Analysis
A broadband cash cow whose valuation sits below normalized owner earnings and whose shareholder returns are large; but the core broadband moat is slowly narrowing under fiber/fixed-wireless competition. Cautious Buy, ideal entry $20-24.
45/100
87Buffett
Costco: A Deep-Dive Value Investing Analysis
A top-tier membership warehouse retailer with outstanding renewal rates and cash flow; but at roughly $1,074 the stock trades at about 56x earnings and 52x owner earnings, far above its optimistic range and with too thin a margin of safety. Rating Watch: an excellent company at a poor price, with an ideal buy range of $500-650.
49/100
91Buffett
Copart Deep Value Investment Analysis
Copart is a salvage and vehicle-disposition auction platform with high margins and a near debt-free balance sheet. The core thesis is that its national yard network, global buyer liquidity, insurer relationships, title-processing capability, and operating systems make it a durable compounder, but at roughly $33 the margin of safety is not obvious. Research rating Watch: wait for a better entry point, with an ideal buy range of $22-26.